Phase I and pharmacokinetic study of the vascular-disrupting agent CKD-516 (NOV120401) in patients with refractory solid tumors.
Kim HK, Kang JW, Park YW, Kim JY, Kim M, Kim SJ, Kim SM, Ho Ryu K, Yoon S, Kim Y, Cho JY, Lee KS, Yun T, Kim K, Kwak MH, Kim TS, Chung J, Park JW.
Kim HK, et al. Among authors: kwak mh.
Pharmacol Res Perspect. 2020 Apr;8(2):e00568. doi: 10.1002/prp2.568.
Pharmacol Res Perspect. 2020.
PMID: 32162844
Free PMC article.
Clinical Trial.